UF-KURE19 CAR-T cells for relapsed/refractory B-cell NHL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This phase 2 trial is testing an experimental CAR-T cell therapy called UF-KURE19 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatment. It may be a new option if you have a CD19-positive lymphoma and meet the study's health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You need to have B-cell non-Hodgkin lymphoma that is CD19-positive (a certain protein on the cancer cells).
- For large B-cell lymphoma: your disease has not responded to or came back after at least one prior therapy, or you cannot receive a stem cell transplant.
- For follicular/marginal zone lymphoma: your disease has come back after at least two prior treatments.
- Your overall health should be fairly good (ECOG score 0–2).
- You must not have had a prior stem cell transplant from a donor or prior CD19 CAR-T therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on B-cell cancer cells. It is for children and adults with B-cell acute lymphoblastic leukemia or certain B-cell lymphomas that have not improved with standard treatments.
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD20 and CD19) on your cancer cells. It is for people with certain types of lymphoma that have not responded to or have come back after at least two prior treatments.
This trial tests whether a new immune therapy (CAR-T cells) can treat certain types of blood cancers that have come back or not responded to standard treatments. It aims to help people with aggressive B-cell lymphoma or acute lymphoblastic leukemia (ALL) that hasn't been controlled by other therapies.
This trial tests a new type of cell therapy (CAR T) that targets two markers on lymphoma cells, CD19 and CD22. It is for people with aggressive B-cell lymphoma that has not responded to standard treatments.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for patients with a specific kind of B-cell lymphoma that has come back or not responded to previous therapy. The treatment targets a protein called CD19 on the cancer cells to help your immune system fight the lymphoma.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Hear when a new Marginal Zone B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.